231 related articles for article (PubMed ID: 25376372)
21. DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing.
Hara RI; Yoshioka K; Yokota T
Methods Mol Biol; 2020; 2176():113-119. PubMed ID: 32865786
[TBL] [Abstract][Full Text] [Related]
22. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates.
Straarup EM; Fisker N; Hedtjärn M; Lindholm MW; Rosenbohm C; Aarup V; Hansen HF; Ørum H; Hansen JB; Koch T
Nucleic Acids Res; 2010 Nov; 38(20):7100-11. PubMed ID: 20615897
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
25. Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats.
Staels B; van Tol A; Chan L; Verhoeven G; Auwerx J
Arterioscler Thromb; 1991; 11(3):760-9. PubMed ID: 1903065
[TBL] [Abstract][Full Text] [Related]
26. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
[TBL] [Abstract][Full Text] [Related]
27. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
28. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide.
Grossman TR; Carrer M; Shen L; Johnson RB; Hettrick LA; Henry SP; Monia BP; McCaleb ML
Mol Vis; 2017; 23():561-571. PubMed ID: 28855795
[TBL] [Abstract][Full Text] [Related]
29. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides.
Wang Y; Diep JK; Yu RZ; Hurh E; Karwatowska-Prokopczuk E; Schneider E; Henry S; Bhanot S; Geary RS
J Clin Pharmacol; 2023 Jan; 63(1):21-28. PubMed ID: 35801818
[TBL] [Abstract][Full Text] [Related]
33. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.
Laxton C; Brady K; Moschos S; Turnpenny P; Rawal J; Pryde DC; Sidders B; Corbau R; Pickford C; Murray EJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3105-14. PubMed ID: 21502629
[TBL] [Abstract][Full Text] [Related]
34. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism.
Watts LM; Manchem VP; Leedom TA; Rivard AL; McKay RA; Bao D; Neroladakis T; Monia BP; Bodenmiller DM; Cao JX; Zhang HY; Cox AL; Jacobs SJ; Michael MD; Sloop KW; Bhanot S
Diabetes; 2005 Jun; 54(6):1846-53. PubMed ID: 15919808
[TBL] [Abstract][Full Text] [Related]
35. Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.
Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
J Lipid Res; 2011 May; 52(5):971-81. PubMed ID: 21364201
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein E-deficient mice created by systemic administration of antisense oligodeoxynucleotides: a new model for lipoprotein metabolism studies.
Morishita R; Gibbons GH; Kaneda Y; Zhang L; Ogihara T; Dzau VJ
J Endocrinol; 2002 Nov; 175(2):475-85. PubMed ID: 12429045
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.
Merki E; Graham M; Taleb A; Leibundgut G; Yang X; Miller ER; Fu W; Mullick AE; Lee R; Willeit P; Crooke RM; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2011 Apr; 57(15):1611-21. PubMed ID: 21474042
[TBL] [Abstract][Full Text] [Related]
38. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.
Moschos SA; Frick M; Taylor B; Turnpenny P; Graves H; Spink KG; Brady K; Lamb D; Collins D; Rockel TD; Weber M; Lazari O; Perez-Tosar L; Fancy SA; Lapthorn C; Green MX; Evans S; Selby M; Jones G; Jones L; Kearney S; Mechiche H; Gikunju D; Subramanian R; Uhlmann E; Jurk M; Vollmer J; Ciaramella G; Yeadon M
Mol Ther; 2011 Dec; 19(12):2163-8. PubMed ID: 21971426
[TBL] [Abstract][Full Text] [Related]
39. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.
Mazur C; Powers B; Zasadny K; Sullivan JM; Dimant H; Kamme F; Hesterman J; Matson J; Oestergaard M; Seaman M; Holt RW; Qutaish M; Polyak I; Coelho R; Gottumukkala V; Gaut CM; Berridge M; Albargothy NJ; Kelly L; Carare RO; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31619586
[TBL] [Abstract][Full Text] [Related]
40. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA; Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
